Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants

@article{Weir2018InfluenceOR,
  title={Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants},
  author={M. Weir and R. Kreutz},
  journal={Mayo Clinic Proceedings},
  year={2018},
  volume={93},
  pages={1503–1519}
}
  • M. Weir, R. Kreutz
  • Published 2018
  • Medicine
  • Mayo Clinic Proceedings
  • Abstract With the growing integration of non–vitamin K antagonist oral anticoagulants (NOACs) into clinical practice, questions have arisen regarding their use in special populations, including groups that may have been underrepresented in clinical trials. Patients with renal impairment, particularly in the lower echelons of renal function, are one such group. In an effort to elucidate the current evidence regarding the use of NOACs in patients with renal impairment, a systematic assessment of… CONTINUE READING
    4 Citations

    References

    SHOWING 1-10 OF 97 REFERENCES
    Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
    • 101
    Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
    • 670
    Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
    • 350
    • Highly Influential
    Dose-finding study of rivaroxaban in hemodialysis patients.
    • 82
    Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    • 98
    • PDF
    Pipe Dreams About Apixaban for Stroke Prevention in Renal Impairment
    • 6
    Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
    • 92
    • PDF
    Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation
    • 45
    Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study
    • 29